Evidence map›Paper›PMID 40824681›Full record

ArticleCancer research2025

Divergent Clonal Evolution and Early Dissemination Promote Genetic Heterogeneity of Metastases in Castration-Resistant Prostate Cancer.

Noshad Hosseini, Rahul Mannan, Ryan J Rebernick, Fengyun Su, Rui Wang, Xuhong Cao, Ana Lako, Dattatreya Mellacheruvu, Jing Hu, Joshi J Alumkal and 5 more

Abstract read
In one paragraph

Article in Cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Noshad HosseiniGilbert S. Omenn Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0003-3761-0198
Rahul MannanMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0002-6642-0468
Ryan J RebernickGilbert S. Omenn Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0002-5532-581X
Fengyun SuMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0003-4868-6745
Rui WangMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0002-5356-9685
Xuhong CaoMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0002-2455-3086
Ana LakoBristol Myers Squibb, Lawrenceville, New Jersey.ORCID 0000-0003-2931-6212
Dattatreya MellacheruvuBristol Myers Squibb, Lawrenceville, New Jersey.ORCID 0000-0001-8221-7673
Jing HuMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0001-7604-6732
Joshi J AlumkalMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0003-1278-0166
Zachery R ReichertDepartment of Internal Medicine, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0003-0356-8796
Rohit MalikBristol Myers Squibb, Lawrenceville, New Jersey.ORCID 0009-0000-5862-9731
Rohit MehraMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0002-6955-8884
Arul M ChinnaiyanMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0001-9282-3415
Marcin P CieslikGilbert S. Omenn Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0002-5467-1040

Funding

Bristol-Myers Squibb (BMS) 19-PAF06614U.S. Department of Defense (DOD) W81XWH-21-1-0824
6 · The paper itself

Abstract

Lethal prostate cancer has passed through at least two evolutionary bottlenecks: acquisition of metastatic potential and development of castration resistance. A better understanding of how this affects genetic heterogeneity across metastatic sites is needed to develop strategies to block metastatic spread and to overcome resistance. By leveraging deep whole-exome sequencing of 93 tumors from 26 patients, we examined patterns of metastatic dissemination and clonal evolution of prostate cancer. Phylogenetic reconstruction and mathematical modeling enabled quantification of the number of mutations and clones in the cancer ecosystem and characterization of each patient's disease as an evolutionary process. Although mutations of the earliest pathogenic genetic drivers of prostate cancer were truncal, most other likely passenger mutations, copy-number alterations, and clones arose after the cancer had spread and were confined to individual metastatic sites because of polyclonal and polyphyletic seeding. Single-tissue sequencing tended to overestimate mutation clonality and, apart from truncal drivers, underestimate mutation rates for both individual patients and cohorts. This study highlights the independent evolution of metastatic lesions, which has implications for diagnostic and targeted therapy strategies. SIGNIFICANCE: Genomic analysis of a multisite metastatic prostate cancer cohort reveals patterns of clonal heterogeneity, dissemination, and evolution, highlighting the need to evaluate multiple samples to fully characterize the clonal architecture of tumors. This article is part of a special series: Driving Cancer Discoveries with Computational Research, Data Science, and Machine Learning/AI .

Indexed as

Clonal EvolutionGenetic HeterogeneityProstatic Neoplasms, Castration-ResistantDNA Copy Number VariationsExome SequencingHumansMaleMutationNeoplasm MetastasisPhylogeny

Identifiers

PMID40824681
PMCPMC12580794

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.